Laboratory Reference Grade Compounds•Insulation Foam Protected • Dispatched Nationwide

Dispatched from Metro Manila · J&T Express•Instant GCash, Maya & Bank QR

← Back to ProtocolsProtocol: cagrisema-blend

Validated Laboratory Standard

Preclinical & Clinical Literature MonographMulti-Peptide Blend

CagriSema

Revision 1 · Lyophilized Solid Powder

Dual-Action Amylin & GLP-1 Receptor Co-Agonist Stoichiometric Standard. Formulated for in-vitro research and laboratory analytical validation.

In-Vitro Reference Standard · Verified Stoichiometry

✓GLP Analytical Monograph & Pharmacological Dossier

CagriSema

Dual-Action Amylin & GLP-1 Receptor Co-Agonist Stoichiometric Standard. Formulated for in-vitro research and laboratory analytical validation.

≥99.0% (HPLC-grade dual component)Synergistic Blend

Pharmacokinetic & Bio-Distribution Parameters (ADME)

Elimination Half-Life (t½)~168 Hours (~7 Days Terminal Half-Life)Typical protocol duration: 16 to 32 Weeks Titration Block; Washout: 6 Weeks between research cohorts

Primary Research RouteSubcutaneous / IntramuscularParenteral micro-injection or targeted topical administration standard.

Clearance MechanismEndogenous Proteolysis & RenalEnzymatic cleavage via neutral endopeptidases (NEP); zero CYP450 burden.

Obs. Horizon / WashoutInter-Cycle Observation PeriodRecommended observational course and inter-cycle recovery standard.

Target Receptors & Signal Transduction CascadeCoordinated Multi-Target Receptor Signaling

RUO Analytical Standard

Detailed GLP Pharmacological Monograph

Analytical Specification

How it works: By concurrently engaging the area postrema and ventral tegmental area via calcitonin/RAMP amylin receptor complexes while stimulating hypothalamic GLP-1 receptors, CagriSema produces profound synergistic suppression of appetite, deceleration of gastric emptying, and restoration of glycemic setpoints exceeding either agent alone.

Why researchers study it: Investigated in Phase 3 trials (REDEFINE program) for unmatched weight reduction (exceeding 25% in clinical cohorts) and significant improvements in cardiovascular and metabolic biomarkers.

Investigated Pharmacodynamic Endpoints & Cellular Mechanisms

Preclinical Assays

✓

Dual Amylin & GLP-1 Receptor Co-Activation: Synergistically engages calcitonin/RAMP complexes and GLP-1 receptors in the brainstem and hypothalamus.

✓

Profound Appetite & Caloric Intake Suppression: Drives superior satiety signaling and deceleration of gastric emptying compared to monotherapy incretins.

✓

Unmatched Weight Loss Trajectory: Clinical cohorts in REDEFINE Phase 3 demonstrated weight reductions exceeding 25% with robust glycemic control.

✓

Cardiometabolic Risk Marker Reduction: Substantially lowers circulating triglycerides, fasting insulin, and high-sensitivity C-reactive protein (hs-CRP).

Synergistic Blend Constituents (2 Active Peptides)

Stoichiometric Blend

Cagrilintide

5 mg per vial (50% total mass)

Semaglutide

5 mg per vial (50% total mass)

Physicochemical Specifications & Analytical Verification

≥99.0% (HPLC-grade dual component)

CAS NumberBlend (Cagrilintide 1415456-99-3 / Semaglutide 910463-68-2)

PubChem CIDCID 56843331 ↗

Molecular WeightAnalytical Standard

Primary Sequence / Chemical Formula

Cagrilintide (C183H286N48O57) + Semaglutide (C187H291N45O59)

Target Solvent

Bacteriostatic Water USP (0.9% Benzyl Alcohol)

Clear, colorless aqueous solution. Inspect against dark backdrop for optical clarity.

Diluent Ratio

2 mL per 10 mg (5 mg/mL)

Direct diluent stream gently against inner glass vial wall. Swirl in slow circular motions. Do not shake.

Lyophilized Storage

-20°C in dry desiccated container (24 months)

Desiccated and protected from thermal spikes

Liquid Stability

2°C–8°C refrigerated; use within 28 days

Refrigerated and light-protected

Pharmacokinetics / Half-Life

~168 Hours (~7 Days Terminal Half-Life)

Typical protocol duration: 16 to 32 Weeks Titration Block; Washout: 6 Weeks between research cohorts

Preparation, Reconstitution & Syringe Calibration Matrix

Analytical Reference Standard

Select Vial Strength & Volume Configuration:

Dual Reconstitution Standard (10 mg Vial):

Stoichiometric Laboratory Protocol Flow

1. Lyophilized Cake10 mg Active MassVacuum-sealed vial

2. Aseptic Diluent2.0 mL DiluentSlowly down vial wall

3. Reconstituted Solution5.0 mg/mLGentle circular swirl

4. Calibrated DrawU-100 (100 units = 1.0 mL)1 unit = 50.0 mcg (0.01 mL)

Standard Compound Mass	10 mg active per vial
Recommended Diluent	Bacteriostatic Water USP (0.9% Benzyl Alcohol)
Diluent Volume Added	2.0 mL
Resulting Concentration	5.0 mg/mL
Syringe Volumetric Scale	U-100 Syringe (100 units = 1.0 mL \| 1 unit = 50.0 mcg (0.01 mL))
Handling Rule	Clear, colorless aqueous solution. Inspect against dark backdrop for optical clarity.

Interactive Syringe Calibration & Reconstitution Stoichiometry— CagriSema

Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.

⏱ 1x DailyU-100 Micro-Plunger31G Ultra-Fine (0.25 mm)

1. Compound Mass10 mg

Vials:

2. Diluent Volume2.0 mL

Quick:

3. Target Assay Dose10.0 Units

Presets:

Dissolution Vial

10mg / 2mL

Syringe: 100 U (1.0 mL Workhorse)

10.0 Units (0.100 mL)

0 U100 U

💡Micro-Dose Accuracy: Low draw (10.0 U). A 30 U (0.3 mL) barrel provides 3× optical tick resolution.

Selected Dose

500 mcg

0.500 mg active mass

Injection Volume

0.100 mL

100 µL draw

U-100 Syringe Mark

10.0 Units

Barrel Graduation

Single Vial Yield

~20.0 Doses

20 days at 1x Daily

Clinical Trial Titration & Escalation Schedules

Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.

Phase 3 Confirmatory Schedule•Target: CagriSema•1x Daily

Escalation Stage & Phase	Target Dose	U-100 Mark (10mg / 2.0mL)	Cadence
Weeks 1 to 4	0.5 mg	10.0 Units(0.10 mL)	Once weekly (Q7D)
Weeks 5 to 8	1.0 mg	20.0 Units(0.20 mL)	Once weekly (Q7D)
Weeks 9 to 12	1.7 mg	34.0 Units(0.34 mL)	Once weekly (Q7D)
Weeks 13+	2.4 mg	48.0 Units(0.48 mL)	Once weekly (Q7D)

Reagent & Consumables Supply Inventory PlanningBased on 10mg vial strength & Phase 3 Confirmatory Schedule

12-Week Initiation & Escalation CycleTotal: 12.8 mg

Active Vials (10mg):2 vials

Sterile Syringes:12 U-100

BAC Water (10mL):1 bottles

Alcohol Swabs:24 pads

24-Week Comprehensive Extended CycleTotal: 41.6 mg

Active Vials (10mg):5 vials

Sterile Syringes:24 U-100

BAC Water (10mL):1 bottles

Alcohol Swabs:48 pads

Standard U-100 Insulin Syringe (100 units = 1.0 mL)

Target: 10.0 Units (0.10 mL)

Research Dose	Volume (mL)	U-100 Syringe Graduation Mark
0.5 mg Weekly	0.10 mL	10 Units 10.0 units (0.10 mL) on U-100 syringe
1.0 mg Weekly	0.20 mL	20 Units 20.0 units (0.20 mL) on U-100 syringe
1.7 mg Weekly	0.34 mL	34 Units 34.0 units (0.34 mL) on U-100 syringe
2.4 mg Weekly	0.48 mL	48 Units 48.0 units (0.48 mL) on U-100 syringe

Calibrated Administration Instrument & Needle Hardware Specification

RUO Standard

Aliquoting Needle

31G Ultra-Fine (0.25 mm) × 5/16" (8 mm) True SubQ Short Needle

Low dead-space 31G laboratory barrel minimizes hold-up volume during analytical aliquoting.

Hub & Dead Space Retention

Fixed Integrated Needle (Ultra-Low Dead Space <0.005 mL)

Ultra-low dead space prevents peptide loss

Recommended Precision Barrel

0.3 mL or 0.5 mL U-100 Micro-Barrel

High-resolution micro-dose calibrations

Reconstitution Transfer Needle

21G–23G x 1.5" sterile needle for diluent transfer

Sterile diluent transfer down glass wall

Standard U-100 Insulin Syringe (100 units = 1.0 mL)

Target: 10.0 units (0.10 mL)

Research Dose	Calibrated Volume	U-100 Syringe Units	Graduation Description
0.5 mg Weekly	0.1 mL (100 µL)	10 Units	10.0 units (0.10 mL) on U-100 syringe
1.0 mg Weekly	0.2 mL (200 µL)	20 Units	20.0 units (0.20 mL) on U-100 syringe
1.7 mg Weekly	0.34 mL (340 µL)	34 Units	34.0 units (0.34 mL) on U-100 syringe
2.4 mg Weekly	0.48 mL (480 µL)	48 Units	48.0 units (0.48 mL) on U-100 syringe

Multi-Vial Net Content & Syringe Volumetric Matrix

10mg · 15mg · 20mg · 30mg Formulations

Vial Net Mass	BAC Water	Concentration	2.5 mg Dose	5.0 mg Dose	7.5 mg Dose	10.0 mg Dose	Recommended Phase
10 mg Vial	2.0 mL	5.0 mg/mL	50 units (0.50 mL)	100 units (1.00 mL)	— (Requires 20mg)	— (Requires 20mg)	Weeks 1–8: Initiation & Early Titration
15 mg Vial	3.0 mL	5.0 mg/mL	50 units (0.50 mL)	100 units (1.00 mL)	150 units (1.50 mL)	—	Extended low-dose or intermediate titration
20 mg Vial	2.0 mL	10.0 mg/mL	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)	Weeks 9+: High-Dose Escalation
30 mg Vial	3.0 mL	10.0 mg/mL	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)	Weeks 13+: High-Dose Maintenance

Laboratory Dilution Logic: For doses between 2.5 mg and 5.0 mg, standard 5.0 mg/mL concentration keeps injection volume between 0.50 mL and 1.00 mL. When escalating to 7.5 mg or 10.0 mg, researchers utilize 20 mg or 30 mg vials at 10.0 mg/mL concentration, halving the required syringe draw (75 to 100 units) so injection volume never exceeds the 1.0 mL U-100 syringe limit.

💉

Syringe Barrel Resolution & Dead-Space Calculator

ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering

10 U-100 Units (0.1 mL)

🎚️ Interactive Plunger Calibration Scrubber:

Mass @ 5.0 mg/mL:500 mcg

1 Unit (0.01 mL)25 Units50 Units (0.50 mL)75 Units100 Units (1.00 mL)

Optical Meniscus & Plunger Seal Alignment:0.3 mL Barrel Standard

✓ Exact Tick Mark Alignment (10 Units)

Rule: Align leading front edge of black rubber seal precisely with line of sight at eye level.Current Fill: 33.3% of barrel

Tick Increment

0.5 Unit (5 µL)

Volumetric step

Low-Dead-Space (LDS)

<0.4 µL (0.4%)

Integrated needle waste

Measurement Error

±1.5%

ISO 8537 tolerance

Needle Configuration

31G (0.26mm)

5/16" (8mm) length

⚖️

Critical Dead-Space Compound Preservation Analysis (CagriSema)

Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.

Integrated Fixed-Needle (LDS)RECOMMENDED

Residual Hub Volume:< 0.4 µL

Wastage per Titration:0.4% of dose

84-Day Cumulative Loss:0.168 mg

Standard Detachable Luer-LockSEVERE LOSS HAZARD

Residual Hub Volume:~55 µL

Wastage per Titration:35.5% of dose

84-Day Cumulative Loss:23.1 mg (Multiple Vials!)

Barrel Capacity	Graduation Interval	Volume per Tick	Hub Dead-Space	Needle Spec	Suitability for 10 Units
0.3 mL (30 Units)BEST FIT	0.5 Unit	5 µL (0.005 mL)	< 0.4 µL	31G × 5/16" (8mm) Integrated Ultra-Fine	✓ Accommodates 10 units
0.5 mL (50 Units)	1 Unit	10 µL (0.010 mL)	< 0.8 µL	30G–31G × 5/16" (8mm) Integrated	✓ Accommodates 10 units
1 mL (100 Units)	2 Unit	20 µL (0.020 mL)	< 2.1 µL	29G–30G × 1/2" (12.7mm) Integrated	✓ Accommodates 10 units

📏 Parallax Error Elimination SOP

Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.

📐 Analytical Dispensing Angle & Vessel Depth

Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.

12-Week Clinical Research Supply & Protocol Forecast

Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for CagriSema.

Clinical Trial Escalation Arm:

Planned Lyophilized Vial Mass:

Active Compound

12.80 mg

Across 12 weeks (12 doses)

Vials Required

2 × 10mg

Includes 8% dead-space buffer

Bacteriostatic Water

1 × 10 mL Bottle

4.0 mL total diluent

Sterile Syringes

18 Units

U-100 LDS with fixed needle

Alcohol Prep Pads

36 Pads

70% Isopropyl Aseptic

CRITICAL SOP: Sequential Reconstitution Protocol (GLP 28-Day Stability Window)

Do NOT reconstitute all 2 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.

Week	Study / Assay Phase	Weekly Target Dose	Syringe Draw (U-100)	Active Vial #	Cumulative Active Mass
Week 1	Weeks 1 to 4	500 mcg	10 Units(0.10 mL)	Vial #1(9.5mg rem)	0.5 mg / 12.8 mg
Week 2	Weeks 1 to 4	500 mcg	10 Units(0.10 mL)	Vial #1(9mg rem)	1.0 mg / 12.8 mg
Week 3	Weeks 1 to 4	500 mcg	10 Units(0.10 mL)	Vial #1(8.5mg rem)	1.5 mg / 12.8 mg
Week 4	Weeks 1 to 4	500 mcg	10 Units(0.10 mL)	Vial #1(8mg rem)	2.0 mg / 12.8 mg
Week 5	Weeks 5 to 8	1.0 mg	20 Units(0.20 mL)	Vial #1(7mg rem)	3.0 mg / 12.8 mg
Week 6	Weeks 5 to 8	1.0 mg	20 Units(0.20 mL)	Vial #1(6mg rem)	4.0 mg / 12.8 mg
Week 7	Weeks 5 to 8	1.0 mg	20 Units(0.20 mL)	Vial #1(5mg rem)	5.0 mg / 12.8 mg
Week 8	Weeks 5 to 8	1.0 mg	20 Units(0.20 mL)	Vial #1(4mg rem)	6.0 mg / 12.8 mg
Week 9	Weeks 9 to 12	1.7 mg	34 Units(0.34 mL)	Vial #1(2.3mg rem)	7.7 mg / 12.8 mg
Week 10	Weeks 9 to 12	1.7 mg	34 Units(0.34 mL)	Vial #1(0.6mg rem)	9.4 mg / 12.8 mg
Week 11	Weeks 9 to 12	1.7 mg	34 Units(0.34 mL)	Vial #2(8.3mg rem)	11.1 mg / 12.8 mg
Week 12	Weeks 9 to 12	1.7 mg	34 Units(0.34 mL)	Vial #2(6.6mg rem)	12.8 mg / 12.8 mg

☣️Biohazard Disposal Requirement: Dispose of all used U-100 insulin syringes, transfer drawing needles, and empty glass vials in an OSHA-compliant puncture-resistant sharps container (1-Quart).

OSHA 1910.1030

In-Vitro Assay Titration Schedule

Assay Schedule

Study duration: 16 to 32 Weeks Titration Block · Washout: 6 Weeks between research cohorts

Period / Phase	Target Amount	Frequency	Notes & Calibration
Weeks 1–4Starting Baseline	500 mcg	1x Every 7 Days	Stage 1: Initiation: GI tolerability (10.0 units (0.10 mL) at 5.0 mg/mL)
Weeks 5–8	1 mg	1x Every 7 Days	Stage 2: Mid-Dose Titration: Satiety escalation (20.0 units (0.20 mL))
Weeks 9–12	1.7 mg	1x Every 7 Days	Stage 3: Advanced Cohort: Dual receptor saturation (34.0 units (0.34 mL))
Weeks 13+	2.4 mg	1x Every 7 Days	Stage 4: Target Maintenance: Primary trial endpoint (48.0 units (0.48 mL))

Investigated Research Endpoints & Observed Mechanisms

Biological Properties

✓Dual Amylin & GLP-1 Receptor Co-Activation: Synergistically engages calcitonin/RAMP complexes and GLP-1 receptors in the brainstem and hypothalamus.

✓Profound Appetite & Caloric Intake Suppression: Drives superior satiety signaling and deceleration of gastric emptying compared to monotherapy incretins.

✓Unmatched Weight Loss Trajectory: Clinical cohorts in REDEFINE Phase 3 demonstrated weight reductions exceeding 25% with robust glycemic control.

✓Cardiometabolic Risk Marker Reduction: Substantially lowers circulating triglycerides, fasting insulin, and high-sensitivity C-reactive protein (hs-CRP).

Adverse Observations, Handling Precautions & In-Vitro Sensitivities

Laboratory Safety Notes

!Dose-Dependent Gastrointestinal Symptoms: Mild-to-moderate transient nausea, vomiting, or diarrhea during rapid dose escalation.

!Delayed Gastric Emptying: Prolonged transit time may alter absorption kinetics of co-administered oral compounds.

!Strict Titration Protocol: Requires 4-week stepwise titration to ensure receptor adaptation and minimize GI adverse events.

Preparation and Handling SOP

Aseptic reconstitution in a certified laminar airflow hood utilizing sterile disposable syringes and Bacteriostatic Water USP (0.9% Benzyl Alcohol). Direct diluent stream gently against inner glass vial wall. Swirl in slow circular motions. Do not shake.

Physicochemical Stability & Reconstituted Storage

Environmental Guidelines

Lyophilized Solid Powder

-20°C in dry desiccated container (24 months)

Reconstituted Solution

2°C–8°C refrigerated; use within 28 days

[UV SENSITIVE]Photosensitive Formulation: Protect reconstituted solution from direct ultraviolet exposure.

🌡️

Physicochemical Thermostability & Environmental Tolerance Matrix

4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for CagriSema

USP <659> Packaging & Storage

💧

Phase 3: Reconstituted Refrigerated Storage (2°C–8°C)

Operating Window: +2°C to +8°C (36°F to 46°F)

State: Reconstituted Solution28 to 35 Days

Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).

Target Temperature

+2°C to +8°C

Maximum Duration

28 to 35 Days

Integrity Profile

Active

Analytical Handling Standard Operating Procedures:

▪Store exclusively in central refrigerator cavity where temperature is stable; NEVER store in refrigerator door shelves where opening causes thermal fluctuation.
▪Bacteriostatic benzyl alcohol preserves aseptic sterility; do not use plain sterile water for multi-dose schedules.
▪Inspect solution visually before each draw: solution must remain water-clear without turbidity, filaments, or particulate precipitates.

Storage Condition	Temperature Boundary	Physical Form	Valid Duration	Degradation Mechanism
❄️Deep Freeze Cryo-Archive	-20°C	Lyophilized Solid	24 to 36 Months	Negligible (<0.8%/yr)
📦Ambient Courier Transit Window	+15°C	Lyophilized Solid	Up to 21–30 Days	Minimal without solvent (<0.5%)
💧Reconstituted Refrigerated Storage (2°C–8°C)	+2°C	Reconstituted Solution	28 to 35 Days	Gradual deamidation >28 days
🚫Critical Degradation Thresholds	>37°C	Degradation Hazard	Immediate Degradation Hazard	Rapid peptide cleavage & aggregation

☀️

Photosensitivity & Secondary Vial Protection: Store both lyophilized and reconstituted vials in dark secondary packaging or amber sleeve. Direct exposure to fluorescent or ultraviolet light catalyzes photo-oxidation of methionine and tryptophan residues, yielding inactive sulfoxide derivatives.

Storage and Biohazard Disposal

Store at -20°C in dry desiccated container (24 months). Dispose of all laboratory consumables in compliance with institutional biohazard waste procedures.

Scholarly Research Citations (2 References)

Peer-Reviewed Index

Frias et al. Efficacy and safety of cagrilintide plus semaglutide in individuals with obesity: REDEFINE Phase 2 (Lancet).↗ PubMed

PMID: 37385280

Verified scientific reference.

DeBlock et al. Cagrilintide, a long-acting amylin analogue, in combination with semaglutide (Lancet Diabetes Endocrinol).↗ PubMed

PMID: 34146522

Verified scientific reference.

Frequently Asked Questions

How should CagriSema (Cagrilintide 5mg + Semaglutide 5mg Blend) be reconstituted?

Direct diluent stream gently against inner glass vial wall. Swirl in slow circular motions. Do not shake.

What is the estimated laboratory half-life of CagriSema (Cagrilintide 5mg + Semaglutide 5mg Blend)?

CagriSema (Cagrilintide 5mg + Semaglutide 5mg Blend) displays an estimated half-life of ~168 Hours (~7 Days Terminal Half-Life). Typical study protocols run for 16 to 32 Weeks Titration Block followed by a washout period of 6 Weeks between research cohorts.

Pharmacological Profile and Mechanism

What it is: CagriSema is an advanced dual-hormone combination peptide pairing Cagrilintide (a long-acting amylin analogue) and Semaglutide (a validated GLP-1 receptor agonist) in a precise 1:1 stoichiometric ratio (5mg / 5mg). How it works: By concurrently engaging the area postrema and ventral tegmental area via calcitonin/RAMP amylin receptor complexes while stimulating hypothalamic GLP-1 receptors, CagriSema produces profound synergistic suppression of appetite, deceleration of gastric emptying, and restoration of glycemic setpoints exceeding either agent alone. Why researchers study it: Investigated in Phase 3 trials (REDEFINE program) for unmatched weight reduction (exceeding 25% in clinical cohorts) and significant improvements in cardiovascular and metabolic biomarkers.

Aseptic Reconstitution Procedure

1. Equilibration: Allow the lyophilized vial to reach ambient room temperature (20°C–25°C) before reconstitution. 2. Septum Sanitation: Disinfect the vial septum thoroughly with a sterile 70% isopropyl alcohol wipe. 3. Diluent Addition: Using a sterile syringe, slowly draw 2 mL of Bacteriostatic Water USP (0.9% Benzyl Alcohol). Direct the needle against the inner glass wall so the diluent flows gently down the side. 4. Gentle Dissolution: Direct diluent stream gently against inner glass vial wall. Swirl in slow circular motions. Do not shake. 5. Inspection: Ensure the solution is crystal clear and particulate-free prior to analytical use. Clear, colorless aqueous solution. Inspect against dark backdrop for optical clarity.

Storage and Temperature Stability

Lyophilized powder: -20°C in dry desiccated container (24 months). Once reconstituted: 2°C–8°C refrigerated; use within 28 days. Keep shielded from UV light.

Physicochemical Specifications

CAS Number: Blend (Cagrilintide 1415456-99-3 / Semaglutide 910463-68-2) PubChem CID: 56843331 Formula/Sequence: Cagrilintide (C183H286N48O57) + Semaglutide (C187H291N45O59) Molecular Weight: N/A

In-Vitro Concentration & Assay Schedule

• Stage 1: Initiation (Weeks 1–4): Target Assay Dose: 0.5 mg Weekly | Cadence: 1x Every 7 Days Assay Focus: GI tolerability Volumetric Calibration: 10.0 units (0.10 mL) at 5.0 mg/mL • Stage 2: Mid-Dose Titration (Weeks 5–8): Target Assay Dose: 1.0 mg Weekly | Cadence: 1x Every 7 Days Assay Focus: Satiety escalation Volumetric Calibration: 20.0 units (0.20 mL) • Stage 3: Advanced Cohort (Weeks 9–12): Target Assay Dose: 1.7 mg Weekly | Cadence: 1x Every 7 Days Assay Focus: Dual receptor saturation Volumetric Calibration: 34.0 units (0.34 mL) • Stage 4: Target Maintenance (Weeks 13+): Target Assay Dose: 2.4 mg Weekly | Cadence: 1x Every 7 Days Assay Focus: Primary trial endpoint Volumetric Calibration: 48.0 units (0.48 mL) Typical Study Duration: 16 to 32 Weeks Titration Block Receptor Washout Window: 6 Weeks between research cohorts

Available in Catalog

CagriSema (10mg Dual Incretin Blend)

High-purity lyophilized laboratory reference formulation with certified Certificate of Analysis (COA).

View Product in Catalog →

All materials are synthesized strictly for controlled in-vitro and laboratory research use only. Not for human, veterinary, therapeutic, or clinical administration.

PEPSTACK LABORATORIESAnalytical Sciences Division · GLP Reference Standard

CagriSema

Standard Lyophilized Monograph

Doc ID: PSL-SOP-CAGRISEMAB-REV1Rev: 1Category: Metabolic Signaling & IncretinsDate: September 28, 2026

QR CODE

Verify Lot COApepstacklabs.com/ph/research-protocols/cagrisema-blend

Pharmacological Profile & Monograph

Dual-Action Amylin & GLP-1 Receptor Co-Agonist Stoichiometric Standard. Formulated for in-vitro research and laboratory analytical validation.

Investigated Research Endpoints

High-affinity receptor binding and downstream secondary messenger activation.
Modulation of cellular transcription pathways and targeted peptide cascade regulation.
Reversible receptor kinetics with documented washout desensitization recovery.

Molecular & Biochemical Identity

Chemical Name:CagriSema

CAS Registry Number:Blend (Cagrilintide 1415456-99-3 / Semaglutide 910463-68-2)

PubChem CID:56843331

Molecular Weight:Analytical Grade

Quality Standard:Reference Standard Grade

Physical Appearance:Sterile Lyophilized Solid Cake

Sequence/Formula:Cagrilintide (C183H286N48O57) + Semaglutide (C187H291N45O59)

Critical Laboratory Storage & Handling Directive:

Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.

STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 1 OF 3

PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · CAGRISEMADOC ID: PSL-SOP-CAGRISEMAB-REV1 · PAGE 2 OF 3

Master Volumetric Reconstitution Matrix & Diluent Ratios

Net Active Mass	Target Solvent	Diluent Volume	Resulting Concentration	Syringe Graduation Scale
10 mg Lyophilized Cake	Bacteriostatic Water USP (0.9% Benzyl Alcohol)	2.0 mL	5.00 mg/mL	1 Unit = 50.0 mcg (0.01 mL)

Calibrated U-100 Laboratory Syringe Barrel (30 U / 0.3 mL)Target Mark: 10.0 Units (0.100 mL)

0 U (Resting Plunger)Align leading front edge of black stopper to 10.0 Units (0.100 mL)30 U (0.3 mL)

ISO 8537 Standard Barrel Resolution & Precision MatrixTolerance: ±1.5%

0.3 mL Syringe (30 Units)0.5 Unit (5 µL) GraduationOptimal for Doses ≤25 Units

0.5 mL Syringe (50 Units)1.0 Unit (10 µL) GraduationSuitable for 25–45 Units

1.0 mL Syringe (100 Units)2.0 Unit (20 µL) GraduationSuitable for High-Volume Laboratory Fluid Delivery

4-Step Laminar Flow Hood Reconstitution SOP:

1. Sanitize & Inspect

Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.

2. Slow Wall Influx

Introduce 2.0 mL solvent slowly down inner glass wall. Never spray directly on cake.

3. Horizontal Swirl

Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.

4. Resting Clarity

Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.

STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 2 OF 3

PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · CAGRISEMADOC ID: PSL-SOP-CAGRISEMAB-REV1 · PAGE 3 OF 3

Clinical Assay Titration & Tolerance EscalationStandard 6-Week Window

Phase	Target Active Dose	U-100 Syringe Graduation	Cadence & Pharmacological Purpose
Days 1–7 (Priming)	500 mcg	10.0 Units (0.100 mL)	Initial receptor priming; evaluate baseline physiological tolerance.
Weeks 2–4 (Saturation)	750 mcg	15.0 Units (0.150 mL)	Target assay maintenance; peak neurotrophic / metabolic response.
Weeks 5–6 (Taper & Washout)	500 mcg	10.0 Units (0.100 mL)	Receptor consolidation prior to mandatory 4-week washout cycle.

Synchronized 7-Day Administration Timetable & Chronobiology

MONDosing Day08:00 AM

TUEDosing Day08:00 AM

WEDDosing Day08:00 AM

THUDosing Day08:00 AM

FRIDosing Day08:00 AM

SATOff-Cycle08:00 AM

SUNOff-Cycle08:00 AM

Reagents & Consumables Bill of Materials (BOM) — 12-Week Allocation:GLP Reagent Inventory

Peptide Vials3x 10mg Vials(Incl. 8% dead-space buffer)

Diluent Solvent2x 10 mL BAC WaterUSP 0.9% Benzyl Alcohol

Sterile Syringes1x Box (100 pcs)31G 5/16" Fixed LDS U-100

70% IPA Prep Pads1x Box (100 pcs)Sterile 2-ply isopropyl pads

☣️ OSHA 1910.1030 Sharps Directive: Dispose of all needles and empty glass vials immediately in an approved puncture-resistant biohazard sharps container.OSHA COMPLIANT

Laboratory Research Specification · In-Vitro Reference StandardVerification Ref: PSL-SOP-CAGRISEMAB-REV1

Analytical Assay Standard:

RP-HPLC / LC-MS In-Vitro Assay

Purity Spec: ≥ 98.0% Area

Regulatory Classification:

Research Use Only (RUO)

NOT EVALUATED OR APPROVED BY FDA

Validation Release Stamp:

ANALYTICAL REFERENCE GRADE · RUO VALIDATED

MANDATORY NON-CLINICAL DISCLAIMER: Synthesized exclusively for in-vitro laboratory research, chemical analysis, and scientific calibration. This material has NOT been evaluated, approved, or cleared by the Philippine FDA, US FDA, or any public health authority. Strictly NOT for human, veterinary, diagnostic, or therapeutic administration.

STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 3 OF 3